Proteomics makes blood test breakthrough for deadly throat cancer

The existing method of departure for EAC diagnosis is a upper endoscopy, an invading test, which is more expensive than $ 2750 in the United States. Although 6.1 million upper endoscopy is performed every year, an amazing 90 percent of the EAC cases are still through cracks.

Promarkereso was able to reduce the major costs and discomfort and discomfort of the upper endoscopies using four protein biobelizes. A registered algorithm is marrying clinical factors such as age, gender and body mass index to provide a simple “traffic light” risk by classifying the results of biobelirts as a risk of low, medium or high EAC development.

Obviously adenocarcinoma is the seventh of cancer and carries some of the highest mortality rates due to modern Western diets and lifestyle factors. Therefore, Promarkereso market potential as a means of diagnosis is very large.

In the future, Proteomics will launch Promarkereso in Australia and have other regions to follow in a short time. The test is also patent protected throughout Europe and China and waiting for more judicial authority.

In addition to targeting sales through GPS and primary health service providers, the company will start the same direct consumer from the channel that it uses for sales of other promotional tests.

While Bosphorus cancer still claims that there are too many life through late detection, Promarkereso’s breakthrough can mark a turning point in global cancer care.

The Proteomics International offers an endless, accurate and non -invasive blood test that opponents or even improves traditional diagnostic methods, and opens doors to an earlier treatment and better survival rates for an attack on billions of dollars.

Does your company on the ASX list do something interesting? Contact: Mattbirney@bullsnbears.com.au